223 related articles for article (PubMed ID: 29332137)
1. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
Poorvu PD; Vaz-Luis I; Freedman RA; Lin NU; Barry WT; Winer EP; Hassett MJ
Breast Cancer Res Treat; 2018 Apr; 168(3):727-737. PubMed ID: 29332137
[TBL] [Abstract][Full Text] [Related]
2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
3. Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States.
Vyas AM; Aroke H; Kogut S
J Natl Compr Canc Netw; 2020 Apr; 18(4):405-413. PubMed ID: 32259787
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
[No Abstract] [Full Text] [Related]
5. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
6. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
7. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
8. Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015).
Daniels B; Kiely BE; Tang M; Tervonen H; Pearson SA
BMC Cancer; 2019 Sep; 19(1):909. PubMed ID: 31510955
[TBL] [Abstract][Full Text] [Related]
9. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.
Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii J; Burstein HJ; Winer EP; Freedman RA
Breast Cancer Res Treat; 2016 Aug; 159(1):151-62. PubMed ID: 27484879
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
11. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Ann Oncol; 2016 Feb; 27(2):256-62. PubMed ID: 26578730
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
13. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.
Gao S; Barber B; Schabert V; Ferrufino C
Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
15. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
16. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
17. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.
Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii H; Winer EP; Freedman RA
Breast Cancer Res Treat; 2015 Jun; 151(3):697-707. PubMed ID: 26022349
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
20. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]